A Study in Healthy Men to Test How BI 456906 is Processed in the Body

Sponsor
Boehringer Ingelheim
Study ID
NCT05421338
Phase
PHASE1
Status
Completed

Conditions

  • Healthy

Eligibility Criteria

Sex
MALE
Age
18 Years - 65 Years
Healthy Volunteers
Accepted

Interventions

  • BI 456906 (C-14) — DRUG
    BI 456906 (C-14)

Study Details

This trial is intended to examine the basic pharmacokinetics of BI 456906 and total \[14C\]-radioactivity, including mass balance, excretion pathways and metabolism following a single subcutaneous (SC) dose of BI 456906 (C-14) in (otherwise) healthy male volunteers with normal body weight, overweight or obesity.

Key Dates

Start date
Jul 4, 2022
Status verified
Dec 2022
Primary completion
Nov 17, 2022
Completion
Nov 17, 2022

Study Design

Enrollment
6 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: BI 456906 (C-14)

Primary Outcome Measure

Fraction of [14C]-radioactivity excreted in urine expressed as percentage of the administered dose over the time interval from 0 to the last quantifiable time point (fe_urine, 0-tz) [ Time Frame: up to 7 weeks ]

Related Studies